NCT07420803NARecruiting

A Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness

Mayo Clinic

Start Date

3/23/2026

Completion Date

3/1/2027

Summary

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with auricular transcutaneous vagus nerve stimulation (aTVNS).

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Age 18-75, Persistent Postural-Perceptual Dizziness (PPPD) diagnosis per International Classification of Vestibular Disorders (ICVD). * Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in. * On stable medications/therapy for ≥4 weeks prior to baseline (if any). Exclusion Criteria: * Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia. * Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (\>1 in past 12 months). * Neck surgery, vagotomy, or any condition interfering with vagal stimulation. * Pregnancy.

Interventions

OTHER

Sham Device

OTHER

Auricular transcutaneous vagus nerve stimulation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Chronic DizzinessPersistent Postural Perceptual Dizziness

Locations

Mayo Clinic in Florida

Jacksonville, Florida 32224

United States